MA40333A - Systèmes et méthodes pour atténuer une euphorie induite par des opioïdes - Google Patents

Systèmes et méthodes pour atténuer une euphorie induite par des opioïdes

Info

Publication number
MA40333A
MA40333A MA040333A MA40333A MA40333A MA 40333 A MA40333 A MA 40333A MA 040333 A MA040333 A MA 040333A MA 40333 A MA40333 A MA 40333A MA 40333 A MA40333 A MA 40333A
Authority
MA
Morocco
Prior art keywords
systems
methods
induced euphoria
attenuating
opioid
Prior art date
Application number
MA040333A
Other languages
English (en)
Inventor
Michele Hummel
Donald J Kyle
Garth Whiteside
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of MA40333A publication Critical patent/MA40333A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Dans certains modes de réalisation, l'invention concerne une méthode d'atténuation ou de prévention de l'euphorie induite par des opioïdes qui consiste à administrer à un patient le nécessitant une quantité efficace de buprénorphine.
MA040333A 2014-09-12 2015-09-14 Systèmes et méthodes pour atténuer une euphorie induite par des opioïdes MA40333A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049989P 2014-09-12 2014-09-12
US201462065393P 2014-10-17 2014-10-17

Publications (1)

Publication Number Publication Date
MA40333A true MA40333A (fr) 2016-03-17

Family

ID=55453711

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040333A MA40333A (fr) 2014-09-12 2015-09-14 Systèmes et méthodes pour atténuer une euphorie induite par des opioïdes

Country Status (11)

Country Link
US (2) US20160074387A1 (fr)
EP (1) EP3190890A4 (fr)
JP (1) JP2017526719A (fr)
KR (1) KR20170052644A (fr)
CN (1) CN107072204A (fr)
AU (1) AU2015314714A1 (fr)
CA (1) CA2961009A1 (fr)
IL (1) IL251049A0 (fr)
MA (1) MA40333A (fr)
TW (1) TW201613590A (fr)
WO (1) WO2016040934A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof
JP2020526500A (ja) 2017-06-30 2020-08-31 パーデュー、ファーマ、リミテッド、パートナーシップ 治療方法及びその剤形
JP7293209B2 (ja) * 2017-10-20 2023-06-19 パーデュー、ファーマ、リミテッド、パートナーシップ 医薬剤形

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1613266A4 (fr) * 2003-04-15 2009-05-06 Theraquest Biosciences Llc Methodes de traitement de la douleur et compositions associees
EP1813276A1 (fr) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Formes de dosage inviolables
JP2011515495A (ja) * 2008-03-26 2011-05-19 オールトランツ インコーポレイティド オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑制経皮製剤
WO2011109743A2 (fr) * 2010-03-04 2011-09-09 Rand Jerry N Effets synergiques d'associations de buprenorphine et d'opioïdes pour le traitement des douleurs
KR20160105948A (ko) * 2010-11-08 2016-09-07 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
MX2014011855A (es) * 2012-04-17 2016-09-09 Purdue Pharma Lp Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides.

Also Published As

Publication number Publication date
IL251049A0 (en) 2017-04-30
US20160074387A1 (en) 2016-03-17
TW201613590A (en) 2016-04-16
US20200276187A1 (en) 2020-09-03
AU2015314714A1 (en) 2017-03-09
EP3190890A4 (fr) 2018-04-25
WO2016040934A1 (fr) 2016-03-17
CN107072204A (zh) 2017-08-18
KR20170052644A (ko) 2017-05-12
CA2961009A1 (fr) 2016-03-17
EP3190890A1 (fr) 2017-07-19
JP2017526719A (ja) 2017-09-14

Similar Documents

Publication Publication Date Title
ZA201804513B (en) Method of treating c3 glomerulopathy
PH12014502322A1 (en) Systems and methods for treating an opioid-induced adverse pharmacodynamic response
EP3016652A4 (fr) Inhibiteurs de shp2 et méthodes de traitement de maladies auto-immunes et associées à la glomérulonéphrite à l'aide d'inhibiteurs de shp2
EP3068353A4 (fr) Systèmes et méthodes d'administration sous-rétinienne d'agents thérapeutiques
SG11201602174SA (en) Systems and methods of treatment using intervention and tasking determination
EP3148640A4 (fr) Systèmes et procédés de stimulation de nerf périphérique pour traiter un tremblement
CA2909335C (fr) Fenfluramine destinee a etre utilisee pour le traitement du syndrome de dravet
PT4316555T (pt) Sistemas para administração de gás terapêutico
IL241134A0 (en) Method and system for treating neuromotor system dysfunction
EP3013407A4 (fr) Système de traitement médical et méthode d'utilisation
EP3157620A4 (fr) Procédé et appareil de traitements de neuromodulation de la douleur et d'autres états
EP3013416A4 (fr) Systèmes et procédés d'administration d'une thérapie au moyen d'un dispositif médical ambulatoire
PH12017501393A1 (en) Methods and compositions for decreasing gastric emptying
IL248060A0 (en) System and method for therapeutic management of cough
SA515370011B1 (ar) طرق لعلاج سرطان باستخدام علاج توليفي من مركب داي هيدرو بيرازينو-بيرازين
EP3057985A4 (fr) Systèmes et procédés permettant de déterminer un plan thérapeutique d'action
MX366329B (es) Producto y metodo para tratar diarrea.
MA40333A (fr) Systèmes et méthodes pour atténuer une euphorie induite par des opioïdes
EP3024422A4 (fr) Systèmes et méthodes de traitement de trouble des voies respiratoires
PL3065751T3 (pl) Sposób leczenia raka i chorób współistniejących
MX2016016667A (es) Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer.
EP3044587A4 (fr) Procédé de traitement et de pronostic de sous-groupes de patients scoliotiques
IL240309A0 (en) A system and method for processing agricultural produce
PL3079495T3 (pl) Medykament i sposób leczenia chorób wrodzonej odpowiedzi immunologicznej
CA3301234A1 (en) Device and method of creating a fluid containment field for administering therapeutics to a nerve